BioStock: Cyxone joins forces with leading rheumatoid arthritis expert

Biotech company Cyxone is in the process of preparing drug candidate Rabeximod for the next clinical stage. Recently, the company announced a collaboration with Professor Costantino Pitzalis, a world leading expert redefining clinical trial design in RA, to advise on the upcoming phase IIb trial. BioStock reached out to professor Pitzalis to hear his view on Rabeximod and what impact the drug candidate potentially can make in the field of rheumatoid arthritis in the current market.

Read the full interview with Professor Costantino Pitzalis at biostock.se:

https://www.biostock.se/en/cyxone-joins-forces-with-leading-rheumatoid-arthritis-expert-2/

This is a pressrelease from BioStock Connecting Innovation & Capital. https://www.biostock.se/